PsyBio Therapeutics Corp. (PSYBF)

0.0074 +0.0009 (+14.62%) At close: 12:47PM EDT

PsyBio Therapeutics Corp.

1624 Washington Street
Denver, CO 80203
United States
513 449 9585
https://www.psybiolife.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Evan Mike Levine	Co-Founder, CEO & Chairman	321k	N/A	1966
Mr. Noah Isidore Davis	CFO, Secretary & Director	239.5k	N/A	1983
Dr. Michael Spigarelli M.B.A., M.B.E., M.D., Ph.D.	Chief Scientific Officer & Chief Medical Officer	292.5k	N/A	1966
Mr. Ross Carmel	Chief Legal Officer & Director	131.67k	N/A	1982
Mr. Andrew Jones	Inventor & Chairman of Scientific Advisory Board	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PsyBio Therapeutics Corp., a biotechnology company, engages in the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. PsyBio Therapeutics Corp. was formerly known as Leo Acquisitions Corp. and changed its name to PsyBio Therapeutics Corp. in January 2021. The company is headquartered in Denver, Colorado.

Corporate Governance

PsyBio Therapeutics Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.